INVIVO THERAPEUTICS HOLDINGS CORP. Form 8-K

Form 8-K April 29, 2014

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

#### FORM 8-K

# CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

April 29, 2014

Date of Report (Date of earliest event reported)

### INVIVO THERAPEUTICS HOLDINGS CORP.

(Exact Name of Registrant as Specified in Charter)

**NEVADA**(State or Other
Jurisdiction of Incorporation)

000-52089 (Commission File Number) **36-4528166** (IRS Employer Identification No.)

One Kendall Square, Suite B14402

Cambridge, Massachusetts 02139

(Address of Principal Executive Offices) (Zip Code)

## Edgar Filing: INVIVO THERAPEUTICS HOLDINGS CORP. - Form 8-K

(617) 863-5500

(Registrant s telephone number, including area code)

#### Edgar Filing: INVIVO THERAPEUTICS HOLDINGS CORP. - Form 8-K

Item 7.01. Regulation FD Disclosure.

On April 29, 2014, InVivo Therapeutics Holdings Corp. posted information regarding its Scaffold clinical study to its website at www.invivotherapeutics.com under Learn More About Our Clinical Study.

#### Edgar Filing: INVIVO THERAPEUTICS HOLDINGS CORP. - Form 8-K

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INVIVO THERAPEUTICS HOLDINGS CORP.

Date: April 29, 2014 By: /s/ Tamara Joseph

Tamara Joseph

SVP, General Counsel & Chief Compliance Officer

3